TORONTO, June 27 /CNW/ - Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP)
("Lorus" or the "Corporation"), a biopharmaceutical company specializing in
the research and development of pharmaceutical products and technologies for
the management of cancer, today announced that it has received a receipt for a
final short form prospectus in relation to the previously announced filing of
a preliminary prospectus in each of the provinces of Canada in connection with
a distribution to its shareholders in eligible jurisdictions outside the
United States of rights exercisable for units of the Corporation (the "Rights
Offering").
